[
  {
    "ts": "2025-07-15T17:45:17+00:00",
    "headline": "Exploring 3 High Growth Tech Stocks In The US Market",
    "summary": "As the U.S. stock market experiences mixed movements with major indexes reaching record highs amidst inflation data and earnings reports, the tech sector stands out with notable rallies spurred by companies like Nvidia. In this dynamic environment, identifying high-growth tech stocks involves looking at those that can leverage current trends such as AI advancements and strategic partnerships to sustain their momentum in a competitive landscape.",
    "url": "https://finance.yahoo.com/news/exploring-3-high-growth-tech-174517536.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "a1464cd8-db67-3a61-a660-7fa2531ae048",
      "content": {
        "id": "a1464cd8-db67-3a61-a660-7fa2531ae048",
        "contentType": "STORY",
        "title": "Exploring 3 High Growth Tech Stocks In The US Market",
        "description": "",
        "summary": "As the U.S. stock market experiences mixed movements with major indexes reaching record highs amidst inflation data and earnings reports, the tech sector stands out with notable rallies spurred by companies like Nvidia. In this dynamic environment, identifying high-growth tech stocks involves looking at those that can leverage current trends such as AI advancements and strategic partnerships to sustain their momentum in a competitive landscape.",
        "pubDate": "2025-07-15T17:45:17Z",
        "displayTime": "2025-07-15T17:45:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FqD7IP1YjoMtOLiC1foWBQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DnvRJ7zmyZqa8oFdfcLgCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/exploring-3-high-growth-tech-174517536.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/exploring-3-high-growth-tech-174517536.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CAI"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "SMCI"
            },
            {
              "symbol": "CRCL"
            },
            {
              "symbol": "ARDX"
            },
            {
              "symbol": "TGTX"
            },
            {
              "symbol": "RCEL"
            },
            {
              "symbol": "ALNY"
            },
            {
              "symbol": "ALKT"
            },
            {
              "symbol": "ASND"
            },
            {
              "symbol": "LITE"
            },
            {
              "symbol": "AVXL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-15T17:30:02+00:00",
    "headline": "Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment",
    "summary": "Vertex Pharmaceuticals (VRTX) experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement agreement for the cystic fibrosis treatment ALYFTREK underscores VRTX's therapeutic expansion and patient outreach, counteracting any potential negative market effects from removing the stock from various value indices like the Russell 1000. Positive news on other fronts like long-term data for...",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-secures-nhs-173002610.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "816cd032-a147-30af-b3f1-08e3a8263ef4",
      "content": {
        "id": "816cd032-a147-30af-b3f1-08e3a8263ef4",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment",
        "description": "",
        "summary": "Vertex Pharmaceuticals (VRTX) experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement agreement for the cystic fibrosis treatment ALYFTREK underscores VRTX's therapeutic expansion and patient outreach, counteracting any potential negative market effects from removing the stock from various value indices like the Russell 1000. Positive news on other fronts like long-term data for...",
        "pubDate": "2025-07-15T17:30:02Z",
        "displayTime": "2025-07-15T17:30:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FqD7IP1YjoMtOLiC1foWBQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DnvRJ7zmyZqa8oFdfcLgCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-secures-nhs-173002610.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-secures-nhs-173002610.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-15T13:10:42+00:00",
    "headline": "EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the European Commission approved the company’s new cystic fibrosis treatment, ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor) for treating cystic fibrosis. The approval comes on the basis of ALYFTREK demonstrating non-inferiority compared to the existing treatment, KAFTRIO, in terms of lung function measurement. “Deutivacaftor/tezacaftor/vanzacaftor […]",
    "url": "https://finance.yahoo.com/news/eu-commission-approves-vertex-pharmaceutical-131042914.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "88088e08-9121-33ff-a6fe-72e243b1f81b",
      "content": {
        "id": "88088e08-9121-33ff-a6fe-72e243b1f81b",
        "contentType": "STORY",
        "title": "EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment",
        "description": "",
        "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the European Commission approved the company’s new cystic fibrosis treatment, ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor) for treating cystic fibrosis. The approval comes on the basis of ALYFTREK demonstrating non-inferiority compared to the existing treatment, KAFTRIO, in terms of lung function measurement. “Deutivacaftor/tezacaftor/vanzacaftor […]",
        "pubDate": "2025-07-15T13:10:42Z",
        "displayTime": "2025-07-15T13:10:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CtXX1asSxnB8WIC8BgHTqg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0mEbKSLOWLb2rA0QXVo_YQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/9424dea817e4dd53df499193fc019daa.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eu-commission-approves-vertex-pharmaceutical-131042914.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eu-commission-approves-vertex-pharmaceutical-131042914.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-15T11:58:14+00:00",
    "headline": "Vertex and NHS England agree reimbursement for Alyftrek",
    "summary": "Alyftrek is approved for individuals aged six years and older with at least one F508del mutation.",
    "url": "https://www.pharmaceutical-technology.com/news/vertex-nhs-sign-reimbursement-agreement/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "cbf53e0b-2ffb-3208-9200-467b9559be14",
      "content": {
        "id": "cbf53e0b-2ffb-3208-9200-467b9559be14",
        "contentType": "STORY",
        "title": "Vertex and NHS England agree reimbursement for Alyftrek",
        "description": "",
        "summary": "Alyftrek is approved for individuals aged six years and older with at least one F508del mutation.",
        "pubDate": "2025-07-15T11:58:14Z",
        "displayTime": "2025-07-15T11:58:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/42092d0610feff3a46a3315bc8bf9f83",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "Alyftrek is a triple-combination therapy intended for cystic fibrosis. Credit: Jo Panuwat D/Shutterstock.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BpUnRbsCebaaWWv62y5tTw--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/42092d0610feff3a46a3315bc8bf9f83.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MJ62hhi2BAhT7_UdzVuOMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/42092d0610feff3a46a3315bc8bf9f83.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/vertex-nhs-sign-reimbursement-agreement/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-nhs-england-agree-reimbursement-115814311.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "NICE.TA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-15T11:37:58+00:00",
    "headline": "Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value",
    "summary": "Over the last 7 days, the United States market has remained flat, yet it has experienced an 11% increase over the past year with earnings projected to grow by 15% annually. In this environment, identifying stocks that may be trading below their estimated value can provide investors with potential opportunities for growth and stability.",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-2-other-stocks-113758974.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "f50100bf-6b02-3097-8c41-a06d5cc2bdff",
      "content": {
        "id": "f50100bf-6b02-3097-8c41-a06d5cc2bdff",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value",
        "description": "",
        "summary": "Over the last 7 days, the United States market has remained flat, yet it has experienced an 11% increase over the past year with earnings projected to grow by 15% annually. In this environment, identifying stocks that may be trading below their estimated value can provide investors with potential opportunities for growth and stability.",
        "pubDate": "2025-07-15T11:37:58Z",
        "displayTime": "2025-07-15T11:37:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/7a92075e7c274cfc915511d1e9d413e3",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AjC6WFcKRlNXu5jk7Ym7jw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/7a92075e7c274cfc915511d1e9d413e3.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_mx5bvivqH7XBECD5Y869g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/7a92075e7c274cfc915511d1e9d413e3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-2-other-stocks-113758974.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-2-other-stocks-113758974.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "FLUT"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "STNE"
            },
            {
              "symbol": "ROKU"
            },
            {
              "symbol": "RPD"
            },
            {
              "symbol": "MP"
            },
            {
              "symbol": "IIIN"
            },
            {
              "symbol": "EE"
            },
            {
              "symbol": "DH"
            },
            {
              "symbol": "CARE"
            },
            {
              "symbol": "AUB"
            },
            {
              "symbol": "AKR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-15T10:31:00+00:00",
    "headline": "Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug",
    "summary": "NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill into late-stage trials.",
    "url": "https://www.biopharmadive.com/news/vertex-alyftrek-uk-merck-hiv-phase-3-atara-resubmission/753030/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "32a9efad-5d18-368f-ac9e-799b0c3dcf15",
      "content": {
        "id": "32a9efad-5d18-368f-ac9e-799b0c3dcf15",
        "contentType": "STORY",
        "title": "Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug",
        "description": "",
        "summary": "NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill into late-stage trials.",
        "pubDate": "2025-07-15T10:31:00Z",
        "displayTime": "2025-07-15T10:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/vertex-alyftrek-uk-merck-hiv-phase-3-atara-resubmission/753030/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-secures-alyftrek-coverage-england-103100926.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "EPIX"
            },
            {
              "symbol": "ATRA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]